Dave Ricks | Chairman, Chief Executive Officer |
Josh Smiley | Chief Financial Officer |
Dan Skovronsky | Chief Scientific Officer |
Anne White | President of Lilly Oncology |
Patrik Jonsson | President of Lilly Bio-Medicines |
Mike Mason | President of Lilly Diabetes |
Sara Smith | Investor Relations |
Mike Czapar | Investor Relations |
Kevin Hern | VP of Investor Relations |
Seamus Fernandez | Guggenheim |
Geoff Meacham | Bank of America |
Tim Anderson | Wolfe Research |
Umer Raffat | Evercore |
Andrew Baum | Citi |
Louise Chen | Cantor |
Terence Flynn | Goldman Sachs |
Chris Schott | JPMorgan |
Vamil Divan | Mizuho |
Carter Gould | Barclays |
Steve Scala | Cowen |
Navin Jacob | UBS |
David Risinger | Morgan Stanley |
Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q2 2020 Earnings Call. At this time all participants are in a listen-only mode. [Operator Instructions] As a reminder, today’s call is being recorded. I will now turn the call over to your host, VP of Investor Relations, Kevin Hern. Please go ahead, sir.